Skip to main content
Premium Trial:

Request an Annual Quote

Getting By With a Little Help

Omeros, a Seattle-based drug discovery firm, is getting an injection of money from Washington State's Life Sciences Discovery Fund and local entrepreneur and billionaire Paul Allen, Xconomy reports. Omeros is trying to come up with therapeutics that bind G-protein coupled receptors — targets that have been deemed "undruggable" by many. "We see the Omeros GPCR technology as a major disruptive opportunity," says Steve Hall, who is the managing director of Allen's Vulcan Capital. Omeros is receiving $20 million from Vulcan and $5 million from the state fund. Under the terms of the deal, Xconomy says that both entities "will have skin in the game with Omeros" as they may receive a percentage of future profits and royalties.

HT: Fierce Biotech

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.